Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood

Gidon Toperoff, Dvir Aran, Jeremy D. Kark, Michael Rosenberg, Tatyana Dubnikov, Batel Nissan, Julio Wainstein, Yechiel Friedlander, Ephrat Levy-Lahad, Benjamin Glaser, Asaf Hellman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

283 Scopus citations

Abstract

Inter-individual DNA methylation variations were frequently hypothesized to alter individual susceptibility to Type 2 Diabetes Mellitus (T2DM). Sequence-influenced methylations were described in T2DM-associated genomic regions, but evidence for direct, sequence-independent association with disease risk is missing. Here, we explore disease-contributing DNA methylation through a stepwise study design: first, a pool-based, genome-scale screen among 1169 case and control individuals revealed an excess of differentially methylated sites in genomic regions that were previously associated with T2DM through genetic studies. Next, in-depth analyses were performed at selected top-ranking regions. A CpG site in the first intron of the FTO gene showed small (3.35%) but significant (P = 0.000021) hypomethylation of cases relative to controls. The effect was independent of the sequence polymorphism in the region and persists among individuals carrying the sequence-risk alleles. The odds of belonging to the T2DM group increased by 6.1% for every 1% decrease in methylation (OR = 1.061, 95% CI: 1.032-1.090), the odds ratio for decrease of 1 standard deviation of methylation (adjusted to gender) was 1.5856 (95% CI: 1.2824-1.9606) and the sensitivity (area under the curve = 0.638, 95% CI: 0.586-0.690; males = 0.675, females = 0.609) was better than that of the strongest known sequence variant. Furthermore, a prospective study in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to T2DM, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators. The data showed that low methylation level at the analyzed sites is an early marker of T2DM and suggests a novel mechanism by which early-onset, inter-individual methylation variation at isolated non-promoter genomic sites predisposes to T2DM.

Original languageAmerican English
Article numberddr472
Pages (from-to)371-383
Number of pages13
JournalHuman Molecular Genetics
Volume21
Issue number2
DOIs
StatePublished - Jan 2012

Bibliographical note

Funding Information:
This work was supported by the United States-Israel Binational Science Foundation (to J.D.K.), the Breast Cancer Research Foundation and The Israeli HPR (to E.L.L.), the Russell Berry Foundation/D Cure (to B.G.), the Israel Cancer Research Fund (to A.H.), the NIH research grant R01HL088884 (to Y.F.) and the Israel Science Foundation (to A.H., to Y.F. and to J.D.K.).

Fingerprint

Dive into the research topics of 'Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood'. Together they form a unique fingerprint.

Cite this